$LTCX has other phase 1/2 in process. 3 potential blockbusters
OpRegen, a retinal pigment epithelium (RPE) cell replacement therapy currently in a Phase 1/2a multi-center clinical trial for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy (GA)
OPC1, an oligodendrocyte progenitor cell therapy for the treatment of acute spinal cord injuries. The trial enrollment is completed in a 25- patient Phase 1/2a multicenter clinical trial with OPC1; this trial was partially funded by the California Institute for Regenerative Medicine (CIRM)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.